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Abstract
Introduction:  Neuroinflammation  has  recently  been  described  in  amyotrophic  lateral  sclerosis
(ALS). However,  the  precise  role  of  such  proinflammatory  cytokines  as  monocyte  chemoattrac-
tant protein-1  (MCP-1)  and  macrophage  inflammatory  protein-1  (MIP-1)  in  ALS  has  not  yet
been determined.  In  this  study,  we  determined  cerebrospinal  fluid  (CSF)  MCP-1  and  MIP-1
levels and  assessed  their  association  with  the  duration  and  severity  of  ALS.
Methods:  Concentrations  of  MCP-1  and  MIP-1  were  determined  in  the  CSF  of  77  patients
diagnosed  with  ALS  and  13  controls.  Cytokine  levels  were  analysed  in  relation  to  ALS  duration
(< 12  months  vs  >  12  months)  and  severity  (<  30  points  vs  >  30  points  on  the  ALS  Functional  Rating
Scale administered  at  hospital  admission).
Results:  Higher  CSF  MIP-1  (10.68  pg/mL  vs  4.69  pg/mL,  P  <  .0001)  and  MCP-1  (234.89  pg/mL
vs 160.95  pg/mL,  P  =  .011)  levels  were  found  in  the  77  patients  with  ALS  compared  to  controls.
There were  no  differences  in  levels  of  either  cytokine  in  relation  to  disease  duration  or  severity.
However, we  did  observe  a  significant  positive  correlation  between  MIP-1  and  MCP-1  in  patients
with ALS.
 Please cite this article as: Martínez HR, Escamilla-Ocan˜as CE, Camara-Lemarroy CR, González-Garza MT, Moreno-Cuevas J, García Sarreón
MA. Incremento de las citoquinas proteína quimiotáctica de monocitos-1 (MCP-1) y proteína inflamatoria macrofágica-1  (MIP-1)  en líquido
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Conclusions:  The  increase  in  MIP-1  and  MCP-1  levels  suggests  that  these  cytokines  may  have
a synergistic  effect  on  ALS  pathogenesis.  However,  in  our  cohort,  no  association  was  found  with
either the  duration  or  the  clinical  severity  of  the  disease.
© 2017  Sociedad  Espan˜ola  de  Neurolog´ıa.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Incremento  de  las  citoquinas  proteína  quimiotáctica  de  monocitos-1  (MCP-1)  y
proteína  inflamatoria  macrofágica-1  (MIP-1) en  líquido  cefalorraquídeo  de
pacientes  con  esclerosis  lateral  amiotrófica
Resumen
Introducción:  En  la  esclerosis  lateral  amiotrófica  (ELA)  se  ha  descrito  recientemente  la
presencia de  neuroinflamación.  Sin  embargo,  no  se  ha  definido  el  rol  de  citoquinas  proinfla-
matrorias como  la  proteína  quimiotáctica  de  monocitos-1  (MCP-1)  y  la  proteína  inflamatoria
macrofágica-1 (MIP-1)  en  ELA.  En  este  estudio  evaluamos  niveles  de  MCP-1  y  MIP-1  en
líquido cefalorraquídeo  (LCR),  analizando  su  participación  en  la  duración  y  gravedad  de  la  ELA.
Métodos:  En  77  pacientes  con  ELA  definida  y  13  sujetos  controles,  se  comparó  el  nivel  de
citoquinas  MCP-1  y  MIP-1  en  LCR.  Se  analizaron  estos  niveles  con  relación  a  la  duración  de
la ELA  (<  12  meses  vs.  >  12  meses)  y  a  la  gravedad  de  esta  determinada  mediante  el  puntaje
obtenido  al  ingreso  en  la  escala  funcional  estratificada  de  la  ELA  (<  30  puntos  vs.  >  30  puntos).
Resultados:  En  los  77  pacientes  con  ELA,  se  encontraron  aumentados  los  niveles  de  MIP-1
(4,69 pg/ml  vs.  10,68  pg/ml,  p  <  0,0001)  y  MCP-1  (160,95  pg/ml  vs.  234,89  pg/ml,  p  =  0,011)  en
comparación  con  sujetos  controles.  No  se  observó  diferencia  de  los  niveles  de  estas  citoquinas
con la  duración  o  la  gravedad  de  la  enfermedad.  Sin  embargo,  observamos  una  correlación
positiva significativa  entre  MIP-1  y  MCP-1  en  pacientes  con  ELA.
Conclusiones:  El  aumento  de  MIP-1  y  MCP-1  sugiere  que  estas  citoquinas  parecen  tener  un
efecto sinérgico  en  la  patogénesis  de  la  ELA.  Sin  embargo,  en  nuestra  cohorte  no  se  asociaron
con la  duración  o  la  gravedad  de  la  ELA.
© 2017  Sociedad  Espan˜ola  de  Neurolog´ıa.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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myotrophic  lateral  sclerosis  (ALS)  is  a  fatal  disease  char-
cterised  by  rapid  deterioration  due  to  selective  death  of
otor  neurons  in  the  cerebral  cortex,  brainstem,  and  spinal
ord.1—3 It  has  traditionally  been  regarded  as  a  neurode-
enerative  process;  however,  its  aetiology  and  pathogenic
echanisms  are  yet  to  be  fully  understood.3,4
Recent  evidence  suggests  that  neuroinflammation  is  a
rominent  pathological  feature  of  motor  neuron  lesions.
his  process  is  characterised  by  microglial  activation,
strogliosis,  and  infiltration  of  monocytes  and  T-cells.5
entral  nervous  system  (CNS)  inflammation  has  been  pro-
osed  as  a  contributing  factor  in  ALS  pathogenesis;  this
rocess  is  immune-mediated  and  involves  proinflamma-
ory  cytokines,  which  play  a  critical  role  in  microglial
ctivation.5—9 Cytokines  are  also  involved  in  the  migration
f  peripheral  monocytes/macrophages  and  other  types  of
eukocytes  into  the  CNS  in  patients  with  ALS.5,10—13
Monocyte  chemoattractant  protein-1  (MCP-1)  and
acrophage  inflammatory  protein-1  (MIP-1), 2  members
f  the  chemokine  CC  subfamily,  are  known  to  play  a  role
n  other  neurodegenerative  diseases.14—16 Increased  MCP-1
xpression  has  been  observed  in  mouse  models  of  ALS
y
t
A
fnd  in  the  spinal  cords  of  patients  with  ALS.12,16 To  our
nowledge,  however,  no  studies  have  reported  MIP-1
xpression  in  patients  with  ALS.  Furthermore,  it  is  yet
o  be  determined  whether  changes  in  the  levels  of  these
ytokines  are  protective  or  detrimental  in  the  context  of
LS.5
In  this  study,  we  compared  cerebrospinal  fluid  (CSF)  MCP-
 and  MIP-1 levels  in  patients  with  ALS  and  controls,  and
nalysed  the  association  with  disease  severity  and  duration.
atients and methods
articipants
e  recruited  77  patients  with  ALS  (mean  age  [standard  devi-
tion]:  50.18  years  [10.85])  and  13  controls  (mean  age:
9.15  years  [11.32])  attended  by  the  neurology  depart-
ents  of  Hospital  Zambrano  Hellion  (Instituto  Tecnológico de  Estudios  Superiores  de  Monterrey,  Mexico)  and  Hospi-
al  Universitario  ‘‘Dr.  José  Eleuterio  González’’  (Universidad
utónoma  de  Nuevo  León,  Mexico).  Controls  were  selected
rom  among  patients  with  headache  attending  the  emer-
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Table  1  CSF  cytokine  levels  in  our  sample;  comparison  between  patients  and  controls,  and  between  patient  subgroups  estab-
lished according  to  disease  duration  and  severity.
Cytokine  Controls  ALS  P
MIP-1  (pg/mL)  4.69  (4.26)  10.68  (7.03)  <  .0001
MCP-1 (pg/mL)  160.95  (147.35)  234.89  (151.12)  .011
< 12  months  ≥12  months  P
MIP-1 (pg/mL)  10.16  (8.48)  11.72  (6.44)  ns
MCP-1 (pg/mL)  232.7  (127.95)  236.2  (158.53)  ns
<30 points  ALSFRS-R  ≥30  points  ALSFRS-R  P
MIP-1 (pg/mL)  10.3  (7.16)  10.75  (7.08)  ns
MCP-1 (pg/mL) 230.7  (108.13)  241.4  (192.59)  ns
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1Values are expressed as medians (interquartile range).
Statistically significant differences are shown in bold.
gency  departments  of  both  centres;  they  showed  no  CSF
or  brain  MRI  alterations  and  were  finally  diagnosed  with
tension-type  headache.
In  the  ALS  group,  diagnosis  was  established  by  a  neurolo-
gist,  according  to  the  El  Escorial  criteria.17 We  gathered  the
following  clinical  data  at  the  time  of  inclusion:  time  from
onset  to  diagnosis,  time  from  diagnosis  to  inclusion  in  the
study,  and  score  on  the  revised  ALS  Functional  Rating  Scale
(ALSFRS-R).18 The  study  was  approved  by  the  research  ethics
committees  of  the  medical  schools  of  both  participating  uni-
versities.
Preparation  of  CSF  samples  and  analysis  of
chemokine levels
After  obtaining  written  informed  consent,  we  gathered  CSF
samples  from  all  participants.  Samples  were  stored  at  −70◦C
before  analysis.  MCP-1  and  MIP-1 levels  were  quantified
using  a  Bio-Plex  Pro  kit  (Bio-Rad  Laboratories,  Inc.,  Her-
cules,  USA),  following  the  manufacturer’s  instructions:  50  L
samples  were  incubated  with  50  L  of  magnetic  micro-
spheres  covered  with  specific  antibodies  for  each  of  the  2
cytokines.  Cytokines  were  discriminated  with  fluorescence
spectroscopy  using  a  laser  flow  cytometer.  After  washing,
a  detection  antibody  was  added  to  each  sample  to  form
sandwich  complexes;  we  subsequently  added  a  streptavidin
phycoerythrin  conjugate.  Finally,  buffer  solution  was  added
to  each  well  to  stop  the  reaction.  Samples  were  analysed
with  the  Bio-Plex  200  system.  The  detection  limit  for  each
cytokine  was  1  pg/mL.
Statistical  analysis
Normally  distributed  data  are  expressed  as  means  (standard
deviation),  and  non-normally  distributed  data  as  medians
(interquartile  range).  The  non-parametric  Mann—Whitney
U  test  was  used  to  compare  CSF  MCP-1  and  MIP-1 lev-
els  between  patients  and  controls.  Patients  were  classified
in  2  groups  according  to  the  time  from  diagnosis  to  inclu-
sion  in  the  study:  less  than  12  months  of  progression  (ALS
<  12  months)  and  over  12  months  of  progression  (ALS  ≥
12  months).  We  also  compared  chemokine  levels  between
patients  scoring  <  30  points  on  the  ALSFRS-R  and  those
(
s
e
Mcoring  ≥  30  points.  The  effect  of  disease  severity  and  dura-
ion  on  MCP-1  and  MIP-1 levels  was  analysed  with  the
ann—Whitney  U  test.  Simple  bivariate  correlations  were
nalysed  with  the  Spearman  rank  correlation.  Statistical
nalysis  was  conducted  using  SPSS  version  20.0.
esults
atients  with  ALS
orty-eight  of  the  77  patients  included  were  men  (62.3%).
nset  was  bulbar  in  20  patients,  spinal  in  53,  and  mixed  in
.  Median  time  from  diagnosis  to  inclusion  in  the  study  was
1  months  (range,  6-19),  and  median  time  from  onset  to
iagnosis  was  10  months  (range,  7-18).
hemokine  levels  in  CSF
he  median  CSF  MCP-1  level  was  234.89  pg/mL  (151.12)  in
atients  with  ALS  and  160.95  pg/mL  (147.35)  in  controls
P  =  .011).  The  median  CSF  MIP-1 level  was  10.68  pg/mL
7.03)  in  patients  with  ALS  and  4.69  pg/mL  (4.26)  in  con-
rols  (P  <  .0001)  (Table  1).  No  differences  in  MCP-1  or  MIP-1
evels  were  observed  between  sexes.
The  median  MIP-1 level  was  11.72  pg/mL  (6.44)
n  patients  with  disease  progression  ≥  12  months  and
0.16  pg/mL  (8.48)  in  those  with  disease  progression  <  12
onths  (P  = .4).  In  the  same  patient  subgroups,  median
CP-1  levels  were  236.2  pg/mL  (158.53)  and  232.7  pg/mL
127.95),  respectively  (P  =  .7).
Regarding  clinical  status,  patients  scoring  ≥  30  points  on
he  ALSFRS-R  showed  a  median  MIP-1 level  of  10.75  pg/mL
7.08)  and  a  median  MCP-1  level  of  241.4  pg/mL  (192.59).
hose  scoring  <  30  points  on  the  scale  showed  median  MIP-
  and  MCP-1  levels  of  10.3  pg/mL  (7.16)  and  230.7  pg/mL
108.13),  respectively.  Patients  with  better  clinical  status
howed  higher  levels  of  both  chemokines,  although  differ-
nces  were  not  statistically  significant  (P  =  .4  and  P  =  .5  for
CP  and  MIP).
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orrelations
e  found  a  significant  positive  correlation  between  MIP-
  and  MCP-1  levels  in  our  sample  as  a  whole  (rho  =  0.365;
 =  .001),  as  well  as  in  the  group  of  patients  with
LS  (rho  =  0.309;  P  =  .006).  No  correlations  were  observed
etween  MIP-1 or  MCP-1  levels  and  age  or  ALSFRS-R  scores
data  not  presented).
iscussion
LS  has  traditionally  been  considered  a  neurodegenera-
ive  disease.1,3 However,  neuroinflammatory  changes,  with
icroglial  activation,  have  been  observed  in  the  motor
ortex  and  spinal  cord  of  patients  with  the  disease.19
he  process  underlying  cell  activation  and  the  signalling
olecules  that  mediate  cell-cell  interactions  in  ALS  are
et  to  be  determined.7 CC  chemokines  (MCP-1  and  MIP-1)
ave  been  found  to  mediate  chronic  inflammation  in  other
eurodegenerative  diseases.15,20,21 Similarly,  recent  studies
escribe  infiltration  of  peripheral  monocytes/macrophages
nto  the  CNS  in  patients  with  ALS.10,11 These  infiltrating
onocytes  express  high  levels  of  MCP-1  and  other  chemotac-
ic  cytokines.12 Increased  MCP-1  levels  have  previously  been
escribed  in  patients  with  ALS16,22,23;  however,  the  mecha-
isms  underlying  this  alteration  are  unknown.16
We  found  significant  increases  in  MCP-1  and  MIP-1 lev-
ls  in  patients  with  a  definite  diagnosis  of  ALS.  CSF  levels
f  both  cytokines  were  also  significantly  correlated.  To  our
nowledge,  this  is  the  first  study  to  suggest  the  involvement
f  MIP-1 in  the  pathogenesis  of  ALS.
Microglial  cells  are  thought  to  modulate  immune  sys-
em  alterations  in  ALS;  the  role  of  peripheral  monocytes
n  the  pathogenesis  of  the  disease  is  more  controversial.24
e  found  increased  CSF  MCP-1  and  MIP-1 levels  in  our
ample,  which  suggests  that  dendritic  cells  and  peripheral
acrophages  may  be  involved  in  the  pathophysiology  of
LS.16 The  lack  of  data  about  a  correlation  with  serum  lev-
ls  of  these  cytokines  prevents  us  from  determining  whether
heir  origin  is  central  or  peripheral  (due  to  blood-brain
arrier  disruption).  Both  types  of  immune  cells  may  alter
-cell  function  and  modulate  innate  and  adaptive  immunity.
owever,  it  is  yet  to  be  determined  whether  their  role  is
athogenic  or  protective.
In  our  sample,  patients  with  longer  disease  duration
howed  slightly  higher  MIP-1 levels  and  lower  MCP-1  lev-
ls  than  those  with  shorter  disease  duration,  although  these
ifferences  were  not  significant.  Our  results  do  not  show
n  association  between  MIP-1 and  MCP-1  levels  and  dis-
ase  severity.  However,  it  is  yet  to  be  determined  at  which
recise  moment  in  the  course  of  the  disease  cytokine  expres-
ion  starts,  and  whether  this  response  is  protective  or
athogenic.16
ALS  is  a  relatively  heterogeneous  entity.4 The  highly
ariable  clinical  expression,  duration,  and  severity  of  the
isease  (as  measured  with  the  ALSFRS-R)  may  explain  the
ack  of  significant  differences  in  MCP-1  and  MIP-1 levels
etween  patient  subgroups.  The  correlation  between  lev-
ls  of  these  cytokines  and  such  variables  as  survival  and
linical  progression  may  help  confirm  the  involvement  of
1H.R.  Martínez  et  al.
ytokine-mediated  inflammation  in  ALS.  Understanding  the
ytokine  environment  over  the  course  of  ALS  and  the  role
f  cytokines  in  disease  progression  is  essential  for  the
evelopment  of  reliable  biomarkers  and  effective  treatment
trategies.  Our  study  has  several  limitations,  including  the
mall  size  and  the  heterogeneity  of  our  sample,  the  small
umber  of  controls,  and  the  lack  of  data  about  serum  MCP-1
nd  MIP-1 levels.  Future  studies  should  also  include  more
bjective  functional  assessment  scales.  In  any  case,  our
tudy  is  the  first  to  detect  elevated  MIP-1 levels  in  patients
ith  ALS  and  to  suggest  that  MIP-1 may  play  a role  in  dis-
ase  pathogenesis.
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